[对于脊髓肌肉缩2型的成年患者的口服修饰性治疗]
Yu A Shpilyukova1, S N Illarioshkin1
1Research Center of Neurology, Moscow, Russia.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
|December 26, 2023
概括
里斯迪普拉姆疗法在患有2型脊髓肌缩 (SMA) 的成年患者中表现出有效性,即使在疾病发病数十年后开始治疗. 患者在运动功能和非运动症状 (如吞和呼吸) 中经历了改善,没有任何不良事件.
科学领域:
- 神经学 神经学
- 罕见疾病 罕见疾病
- 临床治疗学 临床治疗学
背景情况:
- 成年脊椎肌肉缩 (SMA) 疾病修饰疗法的有效性因疾病慢性和治疗开始时的神经缺陷而受到争议.
- 成年SMA患者经常出现显著的长期缺陷,这给治疗干预带来了挑战.
研究的目的:
- 评估risdiplam在2型SMA成年患者的长期有效性和安全性.
- 评估晚发性SMA患者的运动和非运动改善.
主要方法:
- 追溯三名SMA2型成人患者的病例系列.
- 患者在疾病发作后16.5-41年开始接受RISDIPLAM治疗.
- 治疗持续时间为2.5-3年,自2020年以来持续观察.
主要成果:
- 这三名患者均表现出肌肉强度的主观和客观改善,特别是近端和远端手臂肌肉.
- 观察到非运动功能的改善,包括吞和呼吸.
- 在长期治疗risdiplam期间没有报告任何不良事件.
结论:
- 里斯迪普拉姆显示出作为一种有效的疾病修饰疗法的潜力,适用于成人SMA2型患者,无论疾病持续时间如何.
- 该疗法提供了超出运动功能的好处,影响非运动症状,并显示出有利的安全性.
更多相关视频
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
7.7K
05:55Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
Published on: October 3, 2011
60.8K
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Satellite Stem Cells and Muscular Dystrophy
2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Parkinson's Disease: Treatment
274
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
274
Skeletal Muscle Relaxants: Therapeutic Uses
487
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
487
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Myasthenia Gravis: Diagnostic Tests
872
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
872
